Abcam PLC (ABCM)
22.71
+0.16
(+0.71%)
USD |
NASDAQ |
Sep 25, 16:00
22.70
-0.01
(-0.04%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 5.217B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 55.23% |
| Valuation | |
| PE Ratio | 1319.20 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 11.42 |
| Price to Book Value | 5.751 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.1637 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 48.07% |
Profile
| Abcam PLC is a biotechnology company that develops and provides antibodies to life science research and clinical communities. The company's products allow research into the role of signaling and regulatory molecules and proteins in biological pathways. Such research ultimately leads to treatments for diseases such as cancer and immune deficiency disorders. Abcam's focused on broadening its product range, improving speed to market, and accessing underpenetrated consumer groups in its markets. The company also selectively pursues partnerships and acquisitions. |
| URL | https://www.abcam.com |
| Investor Relations URL | https://corporate.abcam.com/investors/ |
| HQ State/Province | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Mid Cap/Growth |
| Next Earnings Release | Mar. 20, 2024 (est.) |
| Last Earnings Release | Aug. 31, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 19, 2020 |
Ratings
Profile
| Abcam PLC is a biotechnology company that develops and provides antibodies to life science research and clinical communities. The company's products allow research into the role of signaling and regulatory molecules and proteins in biological pathways. Such research ultimately leads to treatments for diseases such as cancer and immune deficiency disorders. Abcam's focused on broadening its product range, improving speed to market, and accessing underpenetrated consumer groups in its markets. The company also selectively pursues partnerships and acquisitions. |
| URL | https://www.abcam.com |
| Investor Relations URL | https://corporate.abcam.com/investors/ |
| HQ State/Province | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Mid Cap/Growth |
| Next Earnings Release | Mar. 20, 2024 (est.) |
| Last Earnings Release | Aug. 31, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 19, 2020 |